论文部分内容阅读
目的 探讨细胞角蛋白 19(CYFRA2 1- 1)、癌胚抗原 (CEA)联合检测对良恶性胸腔积液 (以下简称胸液 )的诊断价值。方法 采用放射免疫分析法 (RIA)检测 5 2例良恶性胸液中的 CYFRA 2 1- 1和 CEA。同时检测 16例恶性胸液患者化疗前后血清 CYFRA 2 1- 1、CEA。结果 良恶性胸液中 CYFRA 2 1- 1、CEA差异明显 (P<0 .0 1) ,如以 CYFRA2 1- 1>3.3ng/ml,CEA >15 ng/ml作为阳性判定值 ,则 CYFRA2 1- 1对恶性胸液阳性检出率为 83.3% ,特异性 90 .9% ,CEA阳性检出率为86 .7% ,特异性 95 .4% ,CYFRA2 1- 1与 CEA联合检测对恶性胸液阳性检出率提高到 98.1% ,特异性提高到 10 0 %。结论 联合检测 CYFRA2 1- 1、CEA对良恶性胸液具有较高的鉴别诊断价值 ,并可作为观察化疗效果、病情转归的指标。
Objective To investigate the diagnostic value of combined detection of cytokeratin 19 (CYFRA21-1) and carcinoembryonic antigen (CEA) in benign and malignant pleural effusions (hereinafter referred to as pleural fluid). Methods Radioimmunoassay (RIA) was used to detect CYFRA 21-1 and CEA in 52 benign and malignant pleural fluids. At the same time, serum CYFRA 21-1 and CEA were detected in 16 patients with malignant pleural effusion. Results There were significant differences between CYFRA 21-1 and CEA in benign and malignant pleural fluid (P<0.01). CYFRA2 1>3.3ng/ml, CEA>15ng/ml as positive determination value, CYFRA2 1 - The positive rate of malignant pleural fluid was 83.3%, the specificity was 90.9%, the positive rate of CEA was 86.7%, and the specificity was 95.4%. CYFRA21-1 and CEA were combined to detect malignant lesions. The liquid positive detection rate increased to 98.1% and the specificity increased to 100%. Conclusion Combined detection of CYFRA21-1 and CEA has a high value in the differential diagnosis of benign and malignant pleural effusions, and can be used as an indicator to observe the effect of chemotherapy and prognosis of disease.